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I. INTRODUCTION
Under U.S. law, parents are granted broad power and control over their
children’s bodies. In the healthcare setting, the law vests parents with decisionmaking authority for most medical decisions. 1 This general rule applies when minors
seek to undergo body modification through cosmetic surgery, such as breast
implants.2 Thus, a consenting parent who finds a willing provider to perform breast
implant surgery on a minor can authorize this invasive, but elective, surgery on the
child’s behalf.
1

Parham v. J.R., 442 U.S. 584, 603 (1979) (noting that “parents can and must make”
medical decisions regarding their teenage children); see generally Lawrence Schlam & Joseph
P. Wood, Informed Consent to the Medical Treatment of Minors: Law and Practice, 10
HEALTH MATRIX 141, 148–52 (2000) (explaining that doctors must obtain parental consent
prior to performing most medical procedures on minors).
2
Diana Zuckerman & Anisha Abraham, Teenagers and Cosmetic Surgery: Focus on
Breast Implant and Liposuction, 43 J. ADOLESCENT HEALTH 318, 322 (2008) (stating that an
adolescent under eighteen can undergo cosmetic surgery, including breast implants, as long as
there is parental consent).
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Omnipresent media reports and other cultural portrayals of cosmetic surgery
performed on youth indicate that the parental authority to consent to breast implant
surgery on behalf of minors is real and exercised, rather than simply theoretical. One
news report, for example, profiled several teenaged girls who received breast
implants.3 These teens were sometimes offered breast implants as gifts from parents
to celebrate a momentous birthday or a graduation. 4 Others indicated that their
parents had consented to the procedure to help the teen remedy issues with low selfesteem, or to improve her overall happiness. 5
Regardless of what motivates parents to consent to breast implant surgery for
their children, the available data show that parents are doing so in growing numbers.
For example, between 2010 and 2011 the number of breast implant surgeries
performed on young women ranging from ages thirteen to nineteen increased four
percent.6 In a nation where hundreds of thousands of breast implant surgeries are
performed each year across the general population, 7 year-to-year increases of this
magnitude can equal thousands of additional surgeries performed each year.
In many situations it is perfectly reasonable, and in fact preferable, to allow
parents to consent to medical interventions on the behalf of their minor children.
Parents enjoy a constitutional liberty interest in directing the upbringing of their
children; it is presumed that parents will act in the best interests of their children
when they substitute their experiences and judgment for a child’s in making
important life decisions.8 This article highlights, however, that when it comes to
providing consent for their children to undergo medically unnecessary breast implant
surgery, the rationales underlying the presumption of deference to parents and
medical providers fail. Because there are reasons to believe this traditional consent
framework will not protect the best interests of minors who seek breast implants, this
article argues that it is appropriate for the federal government to mandate a national
minimum age of eighteen for receiving breast implants.
This article begins in Part II by providing a brief background on breast implant
surgery and its prevalence amongst minors. Part III outlines representative situations
in which the federal government sets a national minimum age for access to products
or procedures that can be unsafe for minors. Part IV illustrates scenarios where
national age minimums are not deemed appropriate. Part V explores the rationales
underlying both the use and rejection of age restrictions; it explains why a national
minimum age for breast implants would serve similar policy goals as other agebased access controls. Part VI specifically addresses two primary counterarguments:
highlighting why it is appropriate to impinge on both the physician-patient
3

John Stossel, Why Are Parents Buying Their Girls the Gift of Surgery?, ABC NEWS
(July 16, 2007), http://abcnews.go.com/2020/story?id=875821#.ULk6oYXLQ7A.
4

Id.

5

Id.

6

AM. SOC’Y OF PLASTIC SURGEONS, American Society of Plastic Surgeons 2011 Plastic
Surgery Statistics Report 14 (2012), http://www.plasticsurgery.org/Documents/newsresources/statistics/2011-statistics/2011_Stats_Full_Report.pdf [hereinafter ASPS 2011
Statistics Report].
7

Id. at 8.

8

See infra text accompanying notes 181–190.
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relationship and parental autonomy in the context of breast implants for minors.
Finally, Part VII concludes the article.
II. BACKGROUND ON BREAST IMPLANT SURGERY AND ITS PREVALENCE AMONGST
MINORS
A. The Basics of Breast Implant Surgery
Plastic surgery procedures are typically segmented into two subgroups:
reconstructive and corrective.9 Reconstructive surgery is designed to “correct a clear
abnormality.”10 For example, the correction of a cleft lip or palate is considered
reconstructive surgery. On the other hand, corrective or cosmetic surgery is “defined
as surgery to improve a ‘normal’ appearance.” 11 Corrective and cosmetic surgeries
are performed solely for aesthetic reasons and include procedures such as rhinoplasty
(colloquially called a “nose job”) and breast implant surgery.12
Breast implants are medical devices implanted underneath breast tissue or the
chest muscle. Cosmetically, breast implants are used to increase breast size. Two
types of breast implants are approved for sale by the Food and Drug Administration
(FDA) in the United States: saline-filled and silicone gel-filled.13 The FDA has
formally approved saline-filled breast implants for women eighteen and older, and
silicone gel-filled implants for women twenty-two and older.14 Notably, however, it
is legal for doctors to perform breast implant surgery using either type of implant in
minors under eighteen as an “off-label” use with parental consent.15
Breast implant surgery is typically performed on an outpatient basis and requires
general anesthesia.16 During the procedure, the breast implant device is placed inside
a pocket created under the breast tissue or in the pectoralis major muscle of the
patient.17 Immediately following the breast implant surgery, patients typically
experience postoperative discomfort for several days, must wear a surgical bra for
9

Kuni Simis et al., After Plastic Surgery: Adolescent-Reported Appearance Ratings and
Appearance-Related Burdens in Patient and General Population Groups, 109 PLASTIC &
RECONSTRUCTIVE SURGERY 9, 9–10 (2002); see also Derrick Diaz, Minors and Cosmetic
Surgery: An Argument for State Intervention, 14 DEPAUL J. HEALTH CARE L. 235, 238 (2012).
10

Zuckerman & Abraham, supra note 2, at 318.

11

Id.

12

Id.

13

Medical Devices: Breast Implants, FDA, http://www.fda.gov/medicaldevices/
Productsandmedicalprocedures/implantsandprosthetics/breastimplants/default.htm (last
updated Sept. 17, 2013).
14

Zuckerman & Abraham, supra note 2, at 319.

15

Id. Off-label use of this kind is permissible pursuant to the FDA’s policy of approving
medical products only for the specific uses for which they have been proven safe and
effective, simultaneously allowing physicians to determine if they want to use those products
for other medical purposes. Id.
16

Id.

17

Id.
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two weeks, and are instructed to avoid strenuous exercise for four to six weeks. 18
Beyond the general risks of undergoing any surgery involving intravenous
anesthesia, many other complications can arise from breast implant procedures,
specifically. Most commonly, patients may experience capsular contracture, a
tightening or hardening of the scar tissue surrounding the implant, causing the breast
to feel hard and painful.19 Also common are implant ruptures, leaking, postoperative
bleeding, loss of nipple sensation, scarring, and infection. 20
Furthermore, the medical risks of breast implants steadily increase in the years
following the implant surgery. Breast implants last approximately ten years within
the body, and the likelihood of a capsular contracture or related complication
requiring surgery occurring increases over time. 21 Thus, an adolescent who receives
breast implants may require repeated surgeries, with all of the previously mentioned
associated risks, throughout her lifetime. 22 Additionally, breast implant surgery has
been shown to increase the likelihood of insufficient lactation for breastfeeding.23
Breast implants also interfere with preventative or diagnostic mammography, as
mammography procedures increase the likelihood of implant leakage and rupture,
and breast implants may lead to a failure to detect approximately fifty-five percent of
cancerous breast tumors.24 Overall, the FDA has estimated that forty percent of
patients who undergo breast implant surgery experience at least one serious
complication within three years.25
B. Prevalence of Breast Implant Surgery in the United States
According to statistics compiled by the American Society of Plastic Surgeons
(ASPS), 1.6 million cosmetic surgical procedures were conducted in the United
States in 2011.26 Breast implant surgery has held the title of most common cosmetic
surgical procedure since 2006.27 A total of 307,000 breast implant surgeries were
performed in 2011, an increase of 4% from 2010.28 The national average surgeon or
physician fee for a breast implant surgery is $3,388; as such, U.S. expenditures on
breast implant surgery totaled $1,040,725,840 in 2011.29

18

Id.

19

Id.

20

Id.

21

Id.

22

Id.

23

Id.

24

Id.

25

Stossel, supra note 3.

26

ASPS 2011 Statistics Report, supra note 6, at 5.

27

Id.

28

Id. at 8.

29

Id. at 20.
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C. Prevalence of Breast Implant Surgery Amongst Minors in the United States
Although data for minors is not precisely segmented, ASPS found that people
age thirteen to nineteen had the least number of cosmetic procedures in 2011,
constituting two percent of total surgeries. 30 Specifically, 8,892 breast implant
surgeries were performed on patients aged thirteen to nineteen in 2011, which
constituted three percent of the total number of breast implant surgeries performed
that year.31 Although patients aged thirteen to nineteen may represent a small
proportion of the total number of patients undergoing breast implant surgeries in the
United States, the number of these breast implant surgeries performed on women
thirteen to nineteen increased four percent from 2010 to 2011.32 The American
Society for Aesthetic Plastic Surgery (ASAPS) has also gathered statistics regarding
the prevalence of breast implant surgery among minors. The ASAPS report states
that 125,397 cosmetic surgeries were performed on patients under eighteen in 2010,
representing 1.3% of the total number of cosmetic surgery patients. 33 Furthermore,
the report indicates that 4,153 breast implant procedures were performed on women
under the age of eighteen in 2010, also constituting 1.3% of the total number of
breast implant surgeries conducted in that year. 34 A cosmetic bilateral breast implant
was the most frequently requested surgery amongst minors aged eighteen and under,
at forty-seven percent.35
III. REPRESENTATIVE SITUATIONS IN WHICH THE FEDERAL GOVERNMENT
MAINTAINS AGE-BASED REGULATIONS
A. Tobacco Products
Tobacco sales represent one major area in which the federal government has
successfully mandated a nationwide minimum age, although this federal oversight is
a fairly recent accomplishment. In Philip J. Hilts’ book on the history of the FDA,
Protecting America’s Health, Hilts describes the years leading up to the FDA’s first
statements asserting authority to regulate tobacco products. Hilts notes that “[t]he
FDA had not actively pursued the subject before, not because Congress had
prevented it, or because of anything in the law, but simply because it was a hornet’s
nest. There was no nastier political tangle.”36 Despite the stacked political odds, the
FDA proceeded to investigate the subject of tobacco, addiction, and public health
throughout the early 1990s. Based on this research, the FDA determined that:
the problem was not just that a drug was intentionally being delivered to
smokers, but that the companies initially hooked smokers when they were
30

Id. at 6.

31

Id. at 14.

32

Id.

33

AM. SOC’Y FOR AESTHETIC PLASTIC SURGERY, COSMETIC SURGERY NATIONAL DATA
BANK 10 (2010), http://www.surgery.org/sites/default/files/Stats2010_1.pdf.
34

Id.

35

Id. at 12.

36

PHILIP J. HILTS, PROTECTING AMERICA’S HEALTH: THE FDA, BUSINESS, AND ONE
HUNDRED YEARS OF REGULATION 292 (2003).
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children. At bottom, smoking was a pediatric disease, even if the illness
and death finally struck during adulthood. Thus, ultimately, the object of
planned FDA regulation was not to ban smoking or to go after adult
smokers, but simply to try to reduce the number of children who started. 37
In 1996, as a culmination of these years of study and analysis, the FDA
promulgated a rule that regulated cigarettes and smokeless tobacco as medical
devices and prohibited the sale of nicotine-containing cigarettes and smokeless
tobacco to individuals under the age of eighteen.38 The access restrictions and
advertising controls contained in these regulations were designed to reduce
children’s and adolescents' easy access to cigarettes and smokeless tobacco and to
significantly decrease the amount of positive imagery making these products so
appealing to that age group.39
The FDA’s cigarette regulations were challenged in Coyne Beahm, Inc. v. FDA.40
Although the Supreme Court ultimately struck down the FDA’s rules in FDA v.
Brown & Williamson Tobacco Corp.,41 holding that Congress had excluded tobacco
products from the FDA’s jurisdiction, it was the subject-matter of the rules, rather
than the manner of regulating their sale, that was primarily problematic. In Brown &
Williamson, the Court clearly noted that under 21 U.S.C. § 360j(e) the FDA may
restrict the sale, distribution, or use of a device it has jurisdiction to regulate “if,
because of its potentiality for harmful effect or the collateral measures necessary to
its use, [the FDA] determines that there cannot otherwise be reasonable assurance of
its safety and effectiveness.”42
After this first regulatory attempt failed, there was no nationwide minimum
purchase age for tobacco products until March 2010, when the FDA issued a final
rule prohibiting the sale of cigarettes or smokeless tobacco to people younger than
eighteen.43 This rule was authorized by the Family Smoking Prevention and Tobacco
Control Act of 2009 (the Act); the Act amended the Federal Food, Drug, and
Cosmetic Act (FDCA) to provide the FDA with jurisdictional authority over tobacco
products and required the FDA to issue new rules identical to those it originally

37

Id. at 294.

38

Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco
to Protect Children and Adolescents, 61 Fed. Reg. 44,396, 44,396 (Aug. 28, 1996) (to be
codified at 21 C.F.R. pts. 801, 803, 804, 807, 820 and 897). The FDA determined that
cigarettes and smokeless tobacco were combination products consisting of a drug (nicotine)
and device components intended to deliver nicotine to the body, which FDA may regulate as a
drug/device combination product using the Federal Food, Drug, and Cosmetic Act’s (FDCA)
drug authorities, device authorities, or both. Id. at 44,400.
39

Id. at 44,396.

40

Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374, 1400 (M.D.N.C. 1997).

41

FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 156 (2000).

42

Id. at 129.

43

Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco
to Protect Children and Adolescents, 75 Fed. Reg. 13,225, 13,225 (Mar. 19, 2010) (to be
codified at 21 C.F.R. pt. 1140).
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promulgated in 1996.44 The Congressional findings supporting the Act focused on
the adverse health effects tobacco products pose for children, the prevalence of
tobacco advertising and marketing geared towards adolescents, and the need for
comprehensive restrictions on the sale of tobacco products given the failure of past
efforts focused solely on advertising and marketing restrictions. 45
B. Human Subjects Research on Minors
Federal regulations also restrict the ability of minors to participate in biomedical
research.46 Laws governing human subjects research in the United States grew out of
various ethical guidelines and conventions developed by international organizations
and tribunals beginning after World War II. The Nuremberg Code (the Code),
developed in 1947 at the conclusion of the Nuremberg Military Tribunal trials, first
addressed participation in biomedical research. 47 Although the Code did not
explicitly address guidelines for children as research subjects, the Code did
emphasize the importance of voluntary, informed consent. 48 As such, the guidelines
specify that human subjects participating in research must “have the legal capacity to
give consent; should be so situated as to be able to exercise free power of choice . . .
and should have sufficient knowledge and comprehension of the elements of the
subject matter involved as to enable him to make an understanding and enlightened
decision.”49 Thus, while the Code did not impose explicit age restrictions for
participation in biomedical research, following its principles of voluntary consent
would generally prevent participation in biomedical research by minors. It appeared
that children could not meet the Code’s standards for enlightened decision-making
because they lacked the statutory or common law capacity to give consent to medical
treatment and because they were viewed as unable to comprehend the subject matter
of research and engage in an informed decision-making process.50
The World Medical Association’s Helsinki Declarations were the first
international guidelines to make specific recommendations for children’s
participation in research.51 In 1975, “Helsinki II” explicitly categorized children as a
44
Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, § 102, 123
Stat. 1776, 1778–79 (2009) (codified as amended in scattered sections of 5 U.S.C., 15 U.S.C.,
and 21 U.S.C. (2006)).
45

See id.

46

See generally 45 C.F.R. § 46.101 (2009).

47

TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MILITARY TRIBUNALS UNDER
CONTROL COUNCIL LAW NO. 10, 181–82 (U.S. Gov’t Printing Office, 1949) [hereinafter THE
NUREMBERG CODE]; see also Leonard H. Glantz, Research with Children, 24 AM. J.L. & MED.
213, 213 (1998).
48

THE NUREMBERG CODE, supra note 47, at 182.

49

Id..

50

Leonard H. Glantz, The Law of Human Experimentation with Children, in CHILDREN AS
RESEARCH SUBJECTS: SCIENCE, ETHICS, AND LAW 105, 111–13 (Michael A. Grodin & Leonard
H. Glantz eds., 1994).
51

Ann E. Ryan, Protecting the Rights of Pediatric Research Subjects in the International
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals
for Human Use, 23 FORDHAM INT’L L.J. 848, 869 (2000).
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class of legally incompetent research subjects.52 In 1989, “Helsinki IV” urged that, in
situations where a minor child was in fact able to give consent, the child’s consent
should be required in addition to the consent of the minor’s parent or legal
guardian.53 The International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use’s “Guidelines for
Good Practice” suggested that human subjects who could not provide informed
consent should not participate in non-therapeutic research unless certain conditions,
such as low risks relative to benefits, were met.54
Beyond these international ethical statements, the current U.S. regulatory
framework governing children’s participation in human subjects research was also
shaped by a series of disturbing incidents involving children as research subjects.
One of the most infamous examples of this abusive treatment of underage research
subjects occurred at the Willowbrook State School, a residential facility for mentally
disabled children.55 From the 1950s through the 1970s, children living at
Willowbrook were experimentally infected with hepatitis and observed over the
natural course of the disease.56
As the result of this history, federal laws governing human research subjects
provide for enhanced protections when children are research participants. 57 The
mandate of 45 C.F.R. § 46 applies to human subjects research that is conducted or
supported by any federal department or agency and to entities that receive federal
funding for research, including universities. 58 The regulation categorizes research
into four categories according to degrees of risk and benefit. 59 Research not
involving greater than minimal risk is the most permissive category. 60 “Minimal
risk” means “that the probability and magnitude of harm or discomfort anticipated in
the research are not greater in and of themselves than those ordinarily encountered in
daily life or during the performance of routine physical or psychological
examinations or tests.”61
Research involving greater than minimal risk, but presenting the prospect of
direct benefit to the individual subjects, may be funded if an Institutional Review
Board (IRB) finds that:
52

Id. at 870.

53

See id. at 872–73.

54

Id. at 920–21.

55

Susan Lederer & Michael Grodin, Historical Overview: Pediatric Experimentation, in
CHILDREN AS RESEARCH SUBJECTS: SCIENCE, ETHICS, AND LAW 15, 17 (Michael A. Grodin &
Leonard H. Glantz eds., 1994).
56

Id.

57

See generally 45 C.F.R. § 46.101 (2009).

58

See id.

59

OFFICE FOR HUMAN RESEARCH PROTECTIONS, DEP’T OF HEALTH & HUMAN SERVICES,
INSTITUTIONAL REVIEW BOARD GUIDEBOOK: CHAPTER VI SPECIAL CLASSES OF SUBJECTS
(1993), available at http://www.hhs.gov/ohrp/archive/irb/irb_chapter6.htm (last updated
1993).
60

Id.

61

45 C.F.R. § 46.102(i) (2009).
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(a) The risk is justified by the anticipated benefit to the subjects; (b) The
relation of the anticipated benefit to the risk is at least as favorable to the
subjects as that presented by available alternative approaches; and (c)
Adequate provisions are made for soliciting the assent of the children and
permission of their parents or guardians . . . . 62
Research involving greater than minimal risk and no prospect of direct benefit to
individual subjects, but likely to yield generalizable knowledge about the subject’s
disorder or condition, may be funded if an IRB finds that:
(a) The risk represents a minor increase over minimal risk; (b) The
intervention or procedure presents experiences to subjects that are
reasonably commensurate with those inherent in their actual or expected
medical, dental, psychological, social, or educational situations; (c) The
intervention or procedure is likely to yield generalizable knowledge about
the subjects' disorder or condition which is of vital importance for the
understanding or amelioration of the subjects' disorder or condition; and
(d) Adequate provisions are made for soliciting assent of the children and
permission of their parents or guardians . . . . 63
The language of these regulations suggests that research on children that involves
greater than minimal risk is generally inappropriate, even with parental consent to
participation. At least one court has taken a firm stance on this issue. In Grimes v.
Kennedy Krieger Inst., Inc.,64 the Court of Appeals of Maryland held that parents
simply cannot consent to the participation of a child in non-therapeutic research in
which there is any risk of injury or damage to the health of the subject. 65
On the other hand, it is the policy of the National Institutes of Health (NIH) that
children should be “included in all human subjects research conducted or supported
by the NIH unless there are scientific and ethical reasons not to include them.” 66 This
policy is driven by the need to develop scientific data regarding the risks and
benefits of medical treatments for children. The best way to obtain this data is
through clinical trials conducted on children, rather than relying solely on
extrapolated data obtained from adult clinical trials. 67 Thus, there is a fundamental
tension between the scientific and societal goals for medical research that will
benefit broad population segments and the rights of individual children participating
in biomedical research. While excluding children from medical research could be

62

45 C.F.R. § 46.405 (2009).

63

45 C.F.R. § 46.406 (2009).

64

Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807 (Md. 2001).

65

Id. at 858.

66

NIH Policy and Guidelines on the Inclusion of Children as Participants, in Research
Involving Human Subjects, NAT’L INSTITUTES OF HEALTH (Mar. 6, 1998), http://grants1.nih.
gov/grants/guide/notice-files/not98-024.html.
67

Id.
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considered “an injustice to them as members of a community . . . their inclusion as
individual participants in research may be an illegality to each of them.” 68
C. Female Genital Mutilation
According to World Health Organization estimates, over 140 million women and
girls have undergone female genital mutilation (FGM) worldwide, with the practice
occurring primarily in Africa, Asia, and the Middle East, as well as in some
immigrant communities in North America and Europe. 69 Although FGM is
performed for diverse and complex reasons, for many practitioners and in many
cultures the surgeries are thought to add to the beauty of women and to ensure their
marital prospects.70 Despite these cultural rationales, there is a powerful global
movement resisting the practice of FGM. In the United States, the Federal
Prohibition of Female Genital Mutilation Act outlaws FGM at the federal level. 71
Many states also have specific anti-FGM criminal statutes.72 The laws at the state
level vary tremendously: some forbid FGM entirely, some ban the practice when
performed on minors under eighteen, and some impose criminal liability on the
parental act of consenting to the procedure.73
The federal anti-FGM statute criminalizes the conduct of the individuals who
perform FGM on minors, providing that “whoever knowingly circumcises, excises,
or infibulates the whole or any part of the labia majora or labia minora or clitoris of
another person who has not attained the age of 18 years shall be fined under this title
or imprisoned not more than 5 years, or both.” 74 The federal law also contains two
defenses: first, where the operation is “necessary to the health of the person on
whom it is performed, and is performed by a person licensed in the place of its
performance as a medical practitioner” and second, when the operation is done for
reasons of medical necessity “on a person in labor or who has just given birth.” 75
Finally, the statute states that, when applying the first medical necessity defense, “no
account shall be taken of the effect on the person on whom the operation is to be
performed of any belief on the part of that person, or any other person, that the
operation is required as a matter of custom or ritual.” 76 While the number of
68
Bernard M. Dickens, The Legal Challenge of Health Research Involving Children, 6
HEALTH L.J. 131, 132 (1998).
69

See Sara Corbett, A Cutting Tradition, N.Y. TIMES (Jan. 20, 2008), http://www.nytimes.
com/2008/01/20/ magazine/20circumcision-t.html?_r=0.
70

See Richard A. Shweder, What About Female Genital Mutilation? And Why
Understanding Culture Matters in the First Place, in ENGAGING CULTURAL DIFFERENCES: THE
MULTICULTURAL CHALLENGE IN LIBERAL DEMOCRACIES 216, 224–25, 234–35, 242 (Richard
A. Shweder et al. eds., 2002).
71

See 18 U.S.C. § 116(a) (2000).

72

See Holly Maguigan, Will Prosecutions for “Female Genital Mutilation” Stop the
Practice in the U.S.?, 8 TEMP. POL. & CIV. RTS. L. REV. 391, 393 (1999).
73

See id. at 410.

74

See 18 U.S.C. § 116(a) (2000).

75

See 18 U.S.C. § 116(b)(1)–(b)(2) (2000).

76

See 18 U.S.C. § 116(c) (2000).
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prosecutions under this statute has been quite low, 77 convictions can lead to a variety
of collateral consequences for families involved, including deportation from the
United States and the termination of parental rights.78
IV. SITUATIONS IN WHICH AGE-RELATED ACCESS CONTROLS ARE INAPPROPRIATE
A. Over-the-Counter Diet Drugs
The FDCA empowers the FDA with the statutory authority to regulate the safety,
efficacy, and labeling of prescription and nonprescription drugs. 79 Congress has
codified the distinction between prescription and over-the-counter (OTC) drugs,
explaining that a prescription drug is so designated “because of its toxicity or other
potentiality for harmful effect, or the method of its use, or the collateral measures
necessary to its use, is not safe for use except under the supervision of a practitioner
licensed by law to administer such drug.”80 Accordingly, while prescription drugs
must be dispensed by a pharmacist, OTC drugs can be sold in any retail
establishment on open shelves.81
Generally, OTC drug manufacturers are able to market their drugs without FDA
preapproval by complying with a drug monograph designated by the FDA. 82 As
such, the FDA does not review each OTC drug product and label, but requires
manufacturers to produce labels that follow specific format and content guidelines.
For example, OTC drug labels must include information about ingredients,
directions for proper use, and warnings against unsafe use and side effects. 83 Beyond
these basic requirements, the FDA can establish specific warnings for products that
may cause harm under proper use,84 or require reasonable warnings to reduce
foreseeable risks of harm posed by the product. For example, in 1998, the FDA
observed that the availability in the marketplace of multiple container sizes of OTC
laxative drugs containing sodium phosphates had caused consumer confusion,
leading to accidental overdosing and consumer deaths. 85 Given this potential for
misuse, the FDA required an additional warning stating that “[t]aking more than the
recommended dose in 24 hours can be harmful.” 86
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In 2007, the FDA approved Orlistat, the first OTC diet drug. 87 Orlistat is
designed to prevent the absorption of fat from food to achieve weight-loss; its effects
are similar to laxatives.88 The FDA approved prescription strength Orlistat for weight
management at a dosage of 120 milligrams nearly a decade earlier.89 The OTC
version of Orlistat, marketed under the name Alli, is indicated for weight loss in
overweight adults aged eighteen years and older in a dosage of sixty milligrams, half
that of prescription strength.90 Although Alli’s labeling indicates that it is approved
only for overweight adults, the FDA does not enforce this requirement, and Alli can
be freely purchased in retail establishments and online without age or weight
verification.91
Because OTC weight management drugs like Alli are available without any real
retail access controls, minors under eighteen are free to purchase these drugs and
ignore age restrictions outlined in the product labeling. Indeed, abuse of diet pills by
adolescents is a well-documented national public health problem.92 Data indicates
that, in 2011, six percent of adolescent girls and four percent of adolescent boys
reported past-month use of diet products without physician advice. 93 Although diet
drugs such as Alli are widely available on store shelves and advertised directly to
consumers, abuse of OTC weight management products can cause serious health
problems such as fluid and electrolyte disorders, cardiac arrhythmia, stroke, and
hepatic and renal failure.94
While OTC diet drugs like Alli are currently accessible to minors, despite labeled
contraindications, commentators have called for increased regulatory controls to
limit access and abuse of these drugs by youths. Such suggestions include
designating Alli as behind-the-counter (BTC) pharmacy-only status, which would
enable age verification by pharmacists. 95 Despite these calls for increased regulation
and tighter access controls for minors, the fact remains that teenagers are generally
able to obtain easy access to OTC diet drugs. This is likely so because the FDA has
explicitly considered the safety profile of diet drugs such as Alli, deemed them to be
generally safe without the supervision of a physician, and therefore considers the
benefits of widespread availability to outweigh the potential for misuse in the
marketplace.
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B. Indoor Tanning Beds
The use of tanning beds by minors has come under increased scrutiny in recent
years. Studies indicate that exposure to tanning beds when young is particularly
harmful; for example, exposure to indoor tanning appliances can lead to an
especially high increased risk for skin cancer when the age of first exposure is below
twenty years of age. 96 Moreover, statistics indicate that the use of tanning beds by
minors is quite prevalent; an FDA advisory committee panel found in 2010 that forty
to sixty percent of teenage girls surveyed had used tanning beds in the prior year,
despite being aware of the associated risks of skin cancer. 97 To respond to this
growing problem, many states have enacted legislation that regulates the use of
tanning facilities by minors. Eleven states ban the use of tanning beds for minors
under a specified age, typically fourteen years; twenty-one states have opted instead
to require only parental consent for minors under eighteen. 98 Only California and
Vermont ban all minors under eighteen from using tanning beds, 99 while New Jersey
has a similar ban for minors under the age of seventeen. 100 The federal government,
however, has not imposed a national age restriction for tanning beds.
Although the FDA has not imposed a nationwide minimum age requirement for
indoor tanning, the FDA has authority under 21 U.S.C. § 360j(e) to require that a
device be restricted to use “upon such other conditions as the Secretary may
prescribe in such regulation, if, because of its potentiality for harmful effect or the
collateral measures necessary to its use, the Secretary determines that there cannot
otherwise be reasonable assurance of its safety and effectiveness.” 101
This “upon such other conditions” language would allow the FDA to restrict the
use of tanning beds to persons over the age of eighteen as long as the restriction is
essential to the safe and effective use of tanning beds. 102 Critics of proposed national
age restrictions on tanning bed use argue that the government should not have more
of a say in a teenager’s life than his or her own parents; they also suggest that
minimum age requirements will “drive teens to riskier alternatives like home units
and beaches.”103 On the other hand, advocates of these rules stress the limitations of
96
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parental consent laws, noting that parental consent is often insufficient to protect
minors because parents, like their teenage children, do not understand or do not take
sufficient account of the risks of indoor tanning. 104 Overall, although indoor tanning
can be highly dangerous to the health of minors, tanning beds are widely viewed as
an everyday consumer product. As such, it appears that public sentiment favors
leaving their use and popularity to the regulation of the marketplace.
C. Caffeine in Food, Beverages, and Dietary Supplements
Caffeine is a pervasive ingredient in foods, beverages, and medicines sold in the
United States. While most adult users can regularly ingest caffeine with few shortterm or long-term health effects, caffeine use can contribute to mental and physical
health conditions amongst minors, and early caffeine addiction can lead to
experimentation with more serious, illicit drugs. 105 Nevertheless, caffeinated
products are relatively unregulated. Federal regulatory requirements for caffeine
vary greatly depending on whether the caffeinated product is classified as a food,
drug, or dietary supplement.
The FDA defines “food” as any article, or component of such article, “used for
food or drink.”106 When caffeine is added as an ingredient to existing products, such
as soda, or when foods and beverages such as coffee and chocolate contain caffeine
naturally, caffeine as an additive is classified as a food.107 The FDCA states that
caffeine is “generally recognized as safe when used in cola-type beverages in
accordance with good manufacturing practice.” 108 For beverages, the acceptable
amount of caffeine allowable is 0.02% of the total content. 109 Although caffeine does
not have to be listed as an ingredient when it is a natural component of the food,
solids or beverages to which caffeine is artificially added must list caffeine as an
ingredient on product labeling.110 Manufacturers can evade even these fairly limited
regulatory requirements by marketing their caffeinated products as dietary
supplements, rather than food.111 Dietary supplements are regulated by the Dietary
Supplement Health and Education Act of 1994 (DHSEA). 112 High-caffeine energy
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drinks are commonly sold as dietary supplements in order to avoid the FDA’s
limitations on caffeine content in soft drinks and food labeling requirements. 113
Finally, the FDA defines drugs as any article “intended for use in the diagnosis,
cure, mitigation, treatment, or prevention of disease.” 114 Drugs that contain caffeine
are subject to stricter regulatory controls than caffeinated products classified as food
or dietary supplements.115 For example, the FDA limits the permissible caffeine
content in OTC pain medicines to no more than sixty-five milligrams per dose116 and
requires OTC drugs containing caffeine to include warning labels. 117 Given the
FDA’s varied approaches towards food, dietary supplements, and drugs, it is
possible for the manufacturers of caffeinated products to avoid governmental
controls by carefully crafting their marketing and advertising strategies. What is
more profound is that, regardless of whether a caffeinated product is categorized as a
food, drug, or dietary supplement, these products “may be purchased by adults,
adolescents, and children at nearly every grocery, convenience store, or pharmacy in
the United States. There are no national limitations on the sale or consumption of
most . . . caffeinated products to children.”118 Thus, while minors lack the capacity to
make fully informed decisions about consuming caffeinated products, and are more
negatively impacted by excessive caffeine use than adults, minors are able to
purchase most caffeinated products to the same extent as adults. 119
While limiting the sale of heavily-caffeinated products to children (in particular
to children under the age of twelve, who the FDA has advised should avoid excess
caffeine consumption) could be a feasible regulatory tactic, access restrictions on
food products are generally highly unpopular. 120 New York City Mayor Michael
Bloomberg, dubbed “chief of the national food police,” has received backlash for his
regulatory proposals related to soda.121 Often, food regulations that single out a
113
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particular product or ingredient as unsafe or unhealthy are viewed as arbitrary and
unproductive.122 Moreover, the fact that caffeine is found in countless varieties of the
foods and beverages we consume makes access controls as a regulatory technique
highly burdensome for both retailers and consumers.
V. A NATIONAL MINIMUM AGE REQUIREMENT FOR BREAST IMPLANTS SERVES THE
SAME POLICY GOALS THAT OTHER AGE-RELATED ACCESS CONTROLS ARE
DESIGNED TO FURTHER
A. Similarities to Federal Age Restrictions on Tobacco Products
As discussed above, the quest to impose a national minimum age for the
purchase of tobacco products was motivated by two primary concerns. First, the age
restrictions were deemed appropriate because a key public health issue related to
smoking was an expressly pediatric concern: reducing the risk that minors would
begin smoking at a young age and subsequently become lifelong smokers. Second,
federal legislation and regulation imposing age controls for tobacco products were
driven by concerns that children were both especially vulnerable to, and the express
targets of, destructive industry marketing. 123 Concerns about minors undergoing
breast implant surgery share similar themes. Breast implant surgery poses unique
health and safety risks when the patient is an adolescent.124 Moreover, evidence
suggests that teenagers are highly vulnerable to images in the media depicting
cosmetically enhanced models and feel enormous pressure to “meet a culturally
defined ideal of beauty.” 125 Like age controls for tobacco, therefore, banning access
to breast implant surgery for minors under eighteen would be designed to protect
minors from a uniquely pediatric health concern. Age restrictions in both scenarios
would provide enhanced protection when minors are targeted by pervasive media or
advertising images and would prevent serious and scientifically proven health
consequences from occurring in youths.
B. Similarities to Federal Age Restrictions in the Context of Human Subjects
Research Involving Children
The regulatory framework governing the participation of children in biomedical
research highlights a rationale for federal intervention on the behalf of minors that is
particularly relevant in the context of breast implant surgeries for patients under the
age of eighteen. As discussed above, the regulations that control human subject
research embody a keen skepticism towards parents who give permission to enroll
their children in research trials that would expose the minor to risks without the
promise of an individualized benefit in return. 126 In this way, these regulations seem
to indicate that federal intrusion into the parent-child relationship can be tolerated
where parents intend to expose their children to unnecessary physical risks. This
122
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governing principle is highly applicable in the context of parents who provide
consent for their minor children to undergo medically unnecessary breast implant
surgery. Thus, in both situations, parental consent that would subject a child to
physical risk without the promise of individualized physical benefit for that child
should be closely scrutinized.
C. Similarities to Federal Age Restrictions on the Practice of FGM
Like FGM, breast implant surgery invades the bodily integrity of children to
achieve permanent change in their sexual organs, involves a major surgical
procedure, and carries the risk of serious side effects. FGM and breast implant
surgery are also similar because the parents who consent to both procedures may
share similar motivations. According to Professor Elaine M. Chiu, parents who
consent to breast implant surgery want “to enhance the social acceptability of their
children . . . [and] attain beauty, as measured by the dominant culture.” 127 Chiu also
notes that both procedures are integral to identity; in the case of breast implants,
many girls and their parents turn to breast implant surgery as a means for the child to
attain self-esteem and confidence.128 Despite these numerous similarities, however,
practitioners who perform FGM surgery on minors are subject to criminal
prosecution, while it is entirely legal for physicians to perform breast implant
surgery on individuals under the age of eighteen as an off-label use.129 A lesson that
could be gleaned from the example of FGM is that the federal government disfavors
serious surgical procedures that invade the bodily integrity of minors when done
primarily for cultural purposes, rather than based on medical need. Parental consent
on behalf of a minor for both FGM and breast implant surgery is a decision “that
subordinate[s] the child’s interests for the sake of the parent” and for the sake of
conforming to societal norms. 130 As such, the two procedures should be treated in a
legally similar manner.
D. Differences from Permissive Access to OTC Diet Drugs
OTC drugs that can have harmful effects on minors are freely available to
consumers of all ages in retail establishments, but this permissive access scheme is
designed to further broader policy goals. The principle underlying the regulatory
balance between OTC and prescription medicines is that, when OTC drugs are
generally recognized as safe, allowing access to them on a fairly unrestricted basis
furthers the interests of protecting the public’s health and relieving pharmacists and
the public from burdensome restrictions on dispensing drugs. 131 Thus, for OTC
drugs, the FDA has explicitly considered the safety profile of the drug for all
population segments that could access it in the marketplace and has decided that the
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benefits of widespread access outweigh the need for restrictions on dispensing it. On
the other hand, breast implants are highly-regulated medical devices. When the FDA
approved saline-filled breast implants for women over eighteen and silicone gelfilled implants for women over twenty-two, they determined that there was
insufficient evidence to show that breast implants are safe and effective for minors.
The FDA made no explicit determination whatsoever that minors should be able to
access breast implants in its approval process. Thus, off-label breast implant
surgeries performed on minors only occur when physicians, who have been given
broad flexibility by the FDA in the realm of off-label use, determine, on a case-bycase basis, that these procedures are scientifically supported and in the best interests
of a patient. Like the flexibility built into the OTC versus prescription drug
dichotomy, the flexibility built into the off-label paradigm is designed to protect the
public’s health and make sure people have access to treatments that will be
medically beneficial to them. With off-label access to breast implants, however, this
flexibility is unwarranted. The health of a minor may be compromised by
undergoing breast implant surgery at a young age, and the minor patient is not
physically harmed if she is unable to access the procedure until after she reaches the
age of majority.
E. Differences from Permissive Access to Consumer Products Such as Tanning
Beds and Caffeine
The objections to a national minimum age for tanning bed use highlight a key
theme that frequently runs through the discourse associated with age-related product
access controls: critics often argue that parental oversight should be the primary
control on youth behavior.132 Although it is hardly compelling to suggest that parents
should be free to authorize their children to use indoor tanning beds when there is
scientific and medical consensus that tanning beds are “as carcinogenic as
plutonium, arsenic, mustard gas, or cigarettes,” 133 reasoning along these lines is
potentially more persuasive in the context of tanning beds than it would be in the
context of breast implants for minors. Like breast implants, tanning beds are
regulated by the FDA as medical devices.134 Tanning beds are Class I medical
devices. Class I devices are subject to minimal oversight; tanning beds are in the
same category of medical devices as elastic bandages and examination gowns. 135
Breast implants, on the other hand, are Class III medical devices, the most
stringently regulated category of medical devices. 136 Tanning beds, therefore, are
132
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more like ordinary consumer products than breast implants. Given that parents have
a broad liberty interest in overseeing the everyday rearing of their children,137 it
makes more sense to secure the primacy of parental control and authority in the
context of tanning than it does when a child has a rare confrontation with choices
regarding cosmetic breast implant surgery.
The parental choice rationale is even stronger when it comes to caffeine, which is
a pervasive consumer good, and a fixture in everyday life. The example of caffeine
also highlights some additional differences between regulation of the stimulant and
breast implants. While the scientific evidence suggests that caffeine is not seriously
dangerous for children in its common usages, 138 breast implant surgery carries
significant health risks for minors. Moreover, practically speaking, strict age-based
access controls for breast implants would be less onerous than similar restrictions on
caffeine. The political backlash that would likely erupt if minors were banned from
accessing caffeine makes it hard to imagine that age-based access controls for the
stimulant would be effective or successful. Age-based access controls targeting
physicians and designed to safeguard minors from unnecessary and proven safety
risks would be a different scenario altogether.
VI. PROTECTING MINORS FROM ACCESSING BREAST IMPLANT SURGERY WARRANTS
IMPINGEMENTS ON PHYSICIAN AND PARENTAL AUTONOMY
A. Deference to Physicians Is Inappropriate in the Context of Breast Implants
for Minors
The Food and Drug Administration Modernization Act of 1997 affirms the
longstanding principle of the FDA regulatory regime that the Agency must not “limit
or interfere with the authority of a health care practitioner to prescribe or administer
any legally marketed device to a patient for any condition or disease within a
legitimate health care practitioner-patient relationship.”139 In certain circumstances,
such as when a very ill patient could benefit from a newly-discovered indication of
an approved drug, or when the patient is a member of a population group that is
infrequently included in clinical trials that amass safety and effectiveness data, “offlabel use by prescribers is often appropriate and may represent the standard of
care.”140 Given the need for flexibility and the desire to promote innovation when it
is in the best interests of patients, the FDA merely constrains off-label use by
physicians thusly: physicians using “a product for an indication not in the approved
labeling . . . have the responsibility to be well informed about the product, to base its
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use on firm scientific rationale and on sound medical evidence, and to maintain
records of the product's use and effects.”141
While there are indeed many good reasons to provide the medical profession
with a significant degree of deference when it comes to off-label uses, it is not true
“that physicians need to be unfettered in their prescribing practices to achieve
maximal patient welfare.”142 In fact, off-label uses “for which there is little to no
good evidence of safety or efficacy is antithetical to patient welfare and represents
anachronistic medical ethics.”143 This section sets forth the reasons why breast
implant surgery for minors falls into this latter category of off-label use, justifying
regulatory intrusion into the doctor-patient relationship in order to better protect the
best interests of minor patients.
1.

There Is No Evidence Breast Implant Surgery Is Safe for Minors

Although a policy of non-interference with the physician-patient relationship is
warranted in situations in which intrusions would impede sound medical judgment
and stifle innovation, this rationale fails where the proposed off-label use is not
supported by sound medical evidence of safety. Currently, there is no scientific
evidence supporting off-label use of breast implants for minors. As discussed earlier,
the FDA has approved saline-filled breast implants for women ages eighteen and
older and silicone gel-filled implants for women ages twenty-two and older.144 One
reason that these medical device approvals carry age specifications relates to the fact
that, for both saline-filled and silicone gel-filled breast implants, the core clinical
studies used by manufacturers to obtain FDA approval did not involve younger
research subjects.145 For example, the information in Allergan’s Premarket Approval
(PMA) application for its saline-filled implant indicates that the studies were
conducted on women over the age of eighteen. 146 In the PMA for Allergan’s siliconefilled implant product the minimum age of patients is not specified, but the mean age
of the subjects in the core study was thirty-four.147 Because PMA submissions “must
provide valid scientific evidence collected from human clinical trials showing the
device is safe and effective for its intended use,” the FDA could not approve the
devices for an unstudied population group. 148
141
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Of course, this lack of clinical trial evidence is not dispositive, as almost all offlabel uses will, by definition, lack evidentiary support in PMA submissions and
approval studies. What sets breast implant surgery for minors apart is that, on top of
the lack of clinical trial data suggesting the safety and efficacy of these surgeries
conducted on minors, there is affirmative evidence that minors are more vulnerable
physically and mentally to adverse effects related to breast implants. First, in
addition to the serious side effects associated with all breast implant surgeries,
regardless of the age of the patient, there are specific risks associated with
performing breast implant surgery on adolescents whose bodies are still developing.
The bodies of teenaged girls continue to mature into adulthood; growth charts
indicate that most girls gain weight between the ages of eighteen and twenty-one,
which may affect a girl’s desire or need for breast implant surgery. 149 In addition,
because breast implants only last in the body for an average of ten years, minors who
have breast implant surgeries will necessarily have to undergo successive operations
across their lifetimes.150 In addition to the health risks posed by these additional
surgeries, there will also be significant financial burdens for minors who, at a young
age, sign on to carry the burden of breast implant maintenance with them for a
lifetime. One plastic surgeon interviewed for an article in the New York Times
described her fee structure: “she charges about $7,000 for breast augmentation;
roughly $5,000 to remove implants; roughly $7,500 to replace old implants; and
roughly $9,000 for surgery in which she removes implants and performs a breast lift
using the patient’s own tissue.”151
There is also reason to believe that, psychologically and mentally, minors are
particularly inappropriate candidates for breast implant surgeries. As a general
matter, research indicates that individuals who are drawn to cosmetic surgery in the
first place are particularly vulnerable to reckless behavior. As many as fifteen
percent of “patients seeking cosmetic treatments suffer from body dysmorphic
disorder, a severe mental disorder that affects body perception and often leads
sufferers to seek multiple unnecessary surgeries.” 152 Further, women who have
received breast implants are twice as likely as women of the same age who did not
undergo surgery to commit suicide or die from substance abuse. 153 Moreover, unlike
other medical decisions, cosmetic surgery decisions are highly susceptible to peer
influence.154 Adolescents are especially vulnerable to images in the media depicting
cosmetically enhanced models and feel enormous pressure to “meet a culturally
defined ideal of beauty.” 155 It is precisely this pressure that motivates teen girls to
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seek out cosmetic surgery, and studies indicate that peer influence is one of the most
significant motivating factors for minors who wish to undergo cosmetic surgery. 156
Finally, even though minors only consent to breast implant surgeries through the
substituted judgment of their parents, it is nevertheless troubling that minors lack
fully-formed decision-making capacity when making the request for cosmetic
procedures and putting themselves in this sort of situation. Studies show that teen
brains are not fully developed to make critical decisions.157 For example, MRIs
conducted on adolescents and adults indicate that adolescents “rely more on the
amygdala, the area of the brain associated with the primitive impulses of aggression,
anger, and fear. Adults, on the other hand, tend to rely on the frontal lobes, a cerebral
area associated with impulse control and good judgment.” 158 In a similar vein, other
research shows that the regions of the brain associated with risk assessment and
impulse control do not fully develop until late adolescence or later.159 Furthermore,
studies show that adolescents are incapable of making cost-benefit analyses, score
lower on measures of personal responsibility, and are less capable of viewing
situations with a long-term perspective.160 Because of this, minors take risks to a
greater degree than do adults, undervalue the consequences of their actions, and tend
to make poor judgments. 161
2.

Cosmetic Breast Implant Surgery Is, by Definition, Not Medically
Necessary

Given the evidence that minors are generally inappropriate candidates for breast
implant surgery, it cannot seriously be argued that there is a medical need urgent or
important enough to counsel performing breast implant surgeries on minors in the
face of these serious safety concerns. Indeed, breast implants for minors are wholly
unnecessary. Breast implant surgery is quite unlike other medical interventions
because it involves taking unnecessary physical risks that are not offset by any
physical benefits.162 Although it is possible that psychological or other intangible
benefits may accrue to the cosmetic surgery patient, these theoretical benefits pale in
comparison to the substantial risks of the medical procedure. 163 In addition, the role
of the medical provider in the cosmetic surgery context is quite different, as
compared to other medical interventions. 164 In general medical practice, physicians
act according to professional guidelines, which restrict the use of invasive
procedures to only “those that are medically effective as measured by objective
scientific criteria.”165 This guideline alone can serve as a “safeguard against
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impulsive and reckless decision making.” 166 Cosmetic surgery, on the other hand, is
not focused primarily on medical efficacy because its goals are to achieve “aesthetic
and social improvement.”167 While plastic surgeons are expected to perform only
those surgeries that would benefit a patient, determining the degree to which a
cosmetic procedure will benefit a patient is entirely subjective. Further, no study has
shown that there is any long-term benefit of performing cosmetic surgery on
minors.168 While some plastic surgeons are certainly capable of exercising good
subjective judgments in this terrain, “there is simply no guarantee that a professional
adult decision maker committed to preserving the health of the adolescent can be
counted on to counter impulsive risk taking by adolescents for body modification.” 169
3.

The Medical Profession May Be Amenable to Enhanced Regulation of
Breast Implants for Minors

There are indications from within the medical profession itself that restrictions on
the ability of physicians to perform breast implant surgery on minors may be
acceptable. First, in 2004, the ASPS adopted an official stance against breast implant
surgery for patents under age eighteen.170 While this is not an enforceable standard, it
suggests that at least certain medical professionals consider breast implant surgery
performed on minors to run counter to medical ethics.
Statements made by physicians during the FDA panel hearings regarding breast
implant approvals provide another indication that there is a degree of discomfort
from within the medical profession when it comes to performing breast implant
surgery on minors. During the General and Plastic Surgery Devices Panel hearing on
saline breast implant approval, various stakeholders in attendance raised concerns
about allowing young women access to breast implant surgery. 171 Several physicians
noted that obtaining meaningful informed consent from teenagers and their parents
can often be difficult. According to one speaker, this difficulty is largely related to
the fact that the kind of information being given to potential breast implant surgery
patients is largely “probabilistic information,” and “probabilistic thinking is the most
abstract kind of thinking and the last one to develop in [the] range of skills and
capacity that we have.”172 Several physicians in attendance agreed with this
sentiment based upon their personal interactions with younger patients. For example,
Doctor Charles Bailey noted that, “with respect to interacting with the patients, it’s
not uncommon to be sitting in front of a very young patient where you feel like
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nothing that you’re saying is being heard.”173 Another speaker, Doctor Mark Jewell,
agreed with this sentiment, stating
as your children are in the early 20s and certainly in the teens . . . it’s
immediate gratification now. Don’t bother me with the details. I find that
a lot of the younger people are not—I don’t feel like they are really
listening and so sometimes I will impose a second visit on them or have
them, you know, spend more time reading over the material and come
back and sort of show me that they have an understanding of it. 174
Given that younger patients can have trouble properly processing information
about risks and consequences related to breast implant surgery, it seems unlikely that
they will be active and capable participants in the informed consent process
alongside their parents and physicians. Although Dr. Jewell explicitly stated that he
“would not operate on a 17-year-old,”175 he noted that it is his practice to spend
much more time discussing long-term problems associated with breast implant
surgery with his “very young patients.” 176 Specifically, Dr. Jewell tells these young
patients that they will likely “have at least one or two deflations during the next 50
years and maybe more than that.”177
Other speakers throughout the hearing offered additional concerns: that there is a
lack of scientific data delineating the long-term health effects for young girls who
have received breast implant surgery, and that young patients may suffer from
emotional scars if their implants rupture or the patient finds out many years later that
she will not be able to breastfeed her baby.178 Finally, the speakers also hinted at
issues related to the excessive influence of peer pressure on young girls seeking
cosmetic surgery. Dr. Bailey noted that he sometimes saw young teens brought into
the surgeon’s office by “a mother who is pushing an implant on a daughter because
of her early life experiences, or a boyfriend or a husband.” 179 While Dr. Bailey stated
that it was “not uncommon for [him] to refuse two or three patients a month based
on some of these concerns,” this is merely Dr. Bailey’s personal policy, and not one
that any other surgeon would have any obligation or duty to uphold. 180
Overall, there are several reasons why self-regulation by medical professionals is
insufficient to protect minors who wish to undergo breast implant surgery from
harm. First, there is no evidence that breast implant surgery performed on minors is
safe given both the limitations of scientific data and the unique vulnerabilities and
risk profiles of minors. Second, cosmetic breast implant surgery is never medically
173
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necessary, so there are no public health concerns related to encouraging minors to
delay their surgeries until after the age of majority. Finally, there are indications that
the medical profession itself would approve of federal oversight and regulation of
breast implant surgery for minors. Combined, these factors all support the notion that
breast implant surgery performed on minors is a situation in which the doctor-patient
relationship should not be considered inviolable.
B. Deference to Parents Is Inappropriate in the Context of Breast Implants for
Minors
Parents have a fundamental constitutional right to the care and custody of their
minor children. The Supreme Court has characterized this right as a liberty interest
protected under the Due Process Clause of the United States Constitution and has
affirmed the rights of “parents and guardians to direct the upbringing and education
of children under their control.”181 Accordingly, fit parents are granted the
presumption that they will act in the best interests of their children. The rationale
underlying this presumption is that parents have what children lack in “maturity,
experience, and capacity for judgment when making difficult life decisions;” thus,
“due to their natural bond, parents will act in the best interests of their children.”182
A parent’s liberty interest in the upbringing of his or her child encompasses
medical decision-making on behalf of the minor child, as minors are generally
considered to lack the ability to make mature decisions about their physical wellbeing. Informed consent in the medical decision-making context requires patients to
understand a physician’s disclosure of relevant risks and to exercise competent
judgment. Minors are considered legally incompetent of this sort of evaluation;
instead, physicians obtain informed consent from “parents, who are presumptively
deemed competent on behalf of the minor.”183 Consequently, in most cases, a
physician cannot legally treat an adolescent without parental consent. 184
Although the consent of a parent is typically substituted for that of the minor
patient, there are a few exceptions to this general rule, and parents are unable to
dictate all of a child’s medical decisions. In certain circumstances, a state may
substitute its judgment that a medical procedure is in a child’s best interests, even if
parents do not consent. These situations are ones in which “emergent needs take
priority over parental rights and adolescent incompetence.” 185 The first exception
arises in the context of a medical emergency, defined as “any condition that requires
prompt treatment to alleviate pain or in which delay of treatment could increase the
risk to the health of the patient or, ultimately, anything causing the child to be
frightened or hurt.”186 A second form of exception exists in some jurisdictions that
have created special rules for emancipated minors or “mature minors.” An
emancipated minor attains legal adulthood before reaching the age of maturity and
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has the legal authority to consent to medical treatment without parental consent.187 In
addition, the common law “mature minor doctrine” holds that minors “of sufficient
intelligence and maturity to understand and appreciate both the benefits and risks of
the proposed medical or surgical treatment . . . may consent to the treatment without
parental consent.”188 Generally, the mature minor doctrine applies only to minors
aged fourteen and above, who are deemed socially and psychologically mature
enough to make their own healthcare decisions. 189 The third and final type of
exception is made when minors seek out certain sensitive medical treatments, such
as those for substance abuse, mental health, sexually transmitted diseases, and
adolescent pregnancy.190 When it comes to these types of adult-like interventions, the
minor’s personal constitutional right to bodily integrity figures prominently in the
equation and must be balanced against the parental liberty interest in the family and
childrearing.
Several factors combine together to create the overall rationale underlying the
rules detailed above. First, while adolescents are considered rights-bearing citizens,
certain policy concerns at times require these rights to be circumvented. While it is
true that “constitutional rights do not mature and come into being magically only
when one attains the state-defined age of majority,” it is also true that the peculiar
vulnerabilities of children, the inability of children to make informed and mature
decisions, and the centrality of the parental role in childrearing must all be protected
at the same time.191 Therefore, a state’s interest in protecting minors validly justifies
requirements that minors obtain parental consent before undergoing a medical
procedure or that criminalize conduct involving minors that would be
unconstitutional if applied to adults.192 Another factor that leads courts and
policymakers to restrict the ability of minors to make health care decisions is the
idea that minors play an important role in an autonomous family unit, and it is the
parents who have a constitutionally protected right of control over this domain. 193 In
order to respect familial autonomy, parents are given broad discretion and authority
to raise children as they see fit and make decisions about the care of their children
without interference from the government. It is only when the state’s interest in
protecting children outweighs parental liberty that the state can step in and “[take]
the choice out of the hands of the parents” in the health care context, such as by
requiring mandatory vaccinations or prohibiting procedures such as FGM.194
This legal framework suggests a presumption that parents, in consultation with
doctors, are best situated to determine the best interests of the child. In the context of
consenting to breast implant surgery on the behalf of a minor child, this presumption
does not hold. Primarily, this is so because parental-physician decision-making in
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this context can be marred by conflicts of interest. The philosopher Michael Sandel
has written about the issue of parents seeking enhancements for their children; he
notes that parenthood should involve an appreciation of “children as gifts as they
come, not as objects of our design or products of our will or instruments of our
ambition.”195 Sandel does not imply that parents should “shrink from shaping and
directing the development of their child;” on the contrary, he believes that parents
have an obligation to heal their children and prevent sickness and injury. 196 The
distinction as Sandel sees it, however, is that, while a parent who consents to casting
a child’s broken leg does not reject the child as she came, a parent who consents to a
medical intervention that is purely cosmetic fails to appreciate the child as a gift. The
parent’s imposition of his or her will on the child distorts the parent-child
relationship.197 Thus, when a parent consents to an extreme medical intervention,
geared toward shaping the child toward social acceptability but promising no
demonstrable medical benefit, questions of conflicts of interest on behalf of the
caregiver cause the weight to shift against applying the usual parent-doctor decisionmaking presumption to this decision. 198
In fact, it would not be unprecedented to override parental consent in this sort of
scenario. There are two situations in which the legal system has explicitly removed
parental consent from the equation when there are concerns about the motivations
parents have for consenting to medical interventions or procedures on behalf of their
children. First, most courts have held that parental consent is insufficient to authorize
procedures in which a child would serve as an organ donor; in these situations,
judicial approval is necessary.199 There are two reasons why courts typical displace
parents as decision-makers in this context. First, parents frequently have conflicts of
interest; the beneficiary of the proposed organ donation is often an ill family
member, which makes it hard for parents to independently consider the best interests
of the donor child.200 Second, courts have stated that “extra caution is needed when a
parent wants to consent to a medical procedure that offers no medical benefit to the
child.”201 In Little v. Little, for example, a Texas appellate court found that the
mother of a fourteen-year-old girl could not authorize a transplant of her daughter’s
kidney into her son; the court so held because parents can only authorize “medical
treatment,” defined as “the steps taken to effect the cure of an injury or disease.” 202
Donation of a kidney was not considered medical treatment, even though it might
195
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confer psychological benefits, because donation would not improve the physical
health of the donor.203
Another area in which parental consent is considered inadequate to authorize a
minor’s medical intervention is when parents seek to permit the sterilization of their
children. As with organ donation, potential parental conflicts of interest have played
an important role in the development of this legal framework. Sterilization is
typically proposed for developmentally disabled and mentally ill minors or
incompetent adult children. Parents that seek to obtain sterilization for their children
may be worried that the burden of that child’s future unwanted pregnancy would fall
on them; the desire to avoid this situation can mar the judgment of the parent and
interfere with his or her ability to independently consider the child’s best interests. 204
Overall, although parents typically enjoy broad liberties when it comes to raising
children and making important life decisions on their behalf, the risks to minors
associated with breast implants are sufficient to warrant a degree of governmental
interference in this relationship. This is especially so in the context of cosmetic
surgery for minors. When parents consent to expose their children to real medical
risks during purely cosmetic procedures, with only the promise of social or
psychological benefits accruing to the child, their motivations may be marred by
conflicts of interest. As such, enhanced scrutiny is necessary.
VII. CONCLUSION
This article has attempted to make sense of the policy rationales underlying the
federal government’s imposition of age-based access controls on consumer products,
medical procedures, and other interventions. This article argues that banning breast
implants for minors under the age of eighteen would serve similar policy goals to
age restrictions successfully employed elsewhere, such as for tobacco products,
participation in biomedical research, and female genital mutilation. While critics of
age-based access controls will be quick to attack this proposal as unduly burdening
the autonomy of physicians and parents, this article has also demonstrated that there
are reasons to believe that the traditional parental-physician consent framework will
not protect the best interests of minors who seek breast implants. As such, this article
ultimately calls for consistency. Minimum age restrictions for breast implants would
cause no harm for minor patients, but could avoid serious and unnecessary harms.
Thus, age restrictions should be applied in the context of breast implant surgery for
minors where the relevant policy concerns so dictate.
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